NCT04300062 Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer
| NCT ID | NCT04300062 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2020-08-18 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2020-08-18 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insure later study on molecular mechanism involving the progression of NSCLC and SCLC under ICI. The further analysis of research will be performed in the EA 4340 unity, Biomarkers and Clinical Trials in cancerology and onco-hematology, UVSQ, University of Paris-Saclay.
Eligibility Criteria
Inclusion Criteria: * Diagnosed NSCLC or SCLC; * Patient treated priorly by ICI and progressed under ICI; * Have provided written informed consent for the study; * Be \>/= 18 years of age on day of signing informed consent. Exclusion Criteria: * Patient under guardianship or curatorship; * Unable to provide written informed consent for the study; * Technical impossibility to carry out tissular rebiopsy under local anesthesia.
Contact & Investigator
Etienne Giroux Leprieur, MD, PhD
PRINCIPAL INVESTIGATOR
Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP
Frequently Asked Questions
Who can join the NCT04300062 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04300062 currently recruiting?
Yes, NCT04300062 is actively recruiting participants. Contact the research team at etienne.giroux-leprieur@aphp.fr for enrollment information.
Where is the NCT04300062 trial being conducted?
This trial is being conducted at Boulogne-Billancourt, France.
Who is sponsoring the NCT04300062 clinical trial?
NCT04300062 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Etienne Giroux Leprieur, MD, PhD at Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.